Skip to main content
OpenTrials
Completed

NCT Number: NCT04511845

A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Phase I, open-label, multi-center study

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Locally Advanced or Metastatic Solid Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

National Cancer Center Hospital East, Kashiwa, Chiba, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(Both Part I and Part II)

  • Age >= 18 years at time of signing informed consent form
  • ECOG performance status of 0 or 1
  • Patients with a locally advanced, recurrent, or metastatic solid tumor for which standard therapy either does not exist or has proven ineffective or intolerable

(Part I only)

  • Patients with measurable and/or evaluable disease per RECIST v1.1
  • Patients with MAPK pathway alterations positive solid tumor (i.e., BRAF, K/N/H-RAS mutations)

(Part II only)

  • Patients with measurable disease per RECIST v1.1
  • Patients with KRAS mutated NSCLC (NSCLC cohort)
  • Patients with KRAS mutated Ovarian Cancer (Ovarian Cancer cohort)
  • Patients with RAS mutated solid tumor (Biopsy cohort)

Exclusion criteria

(Both Part I and Part II)

  • Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), unstable angina, or myocardial infarction within the previous 6 months or unstable arrhythmias within the previous 3 months
  • Patients with primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases
  • Patients with current severe, uncontrolled systemic disease (including, but not limited to, clinically significant cardiovascular disease, pulmonary disease, or renal disease, ongoing or active infection)
  • Patients with a history or complication of interstitial lung disease (ILD)

Treatment and study plan

SPYK04

Drug

SPYK04 capsule

Primary outcomes

  1. Safety and tolerability of SPYK04 (Dose limiting toxicities) [Dose escalation]

    Time frame: From first dose until the end of Cycle 1 (approximately 35 days)

    Incidence and nature of DLTs

  2. Safety and tolerability of SPYK04 (Adverse Events) [Dose escalation]

    Time frame: From Cycle 0 Day 1 until 28 days after the last dose of study treatment, assessed up to 42 months (study completion)

    Incidence, nature, and severity of adverse events (AEs) as assessed by the NCI CTCAE v5.0

  3. Safety and tolerability of SPYK04 (Electrocardiograms in triplicate) [Dose escalation]

    Time frame: From first dose until the end of Cycle 1 (approximately 35 days)

    Uncorrected QT interval, QTcF, PR duration, QRS interval and RR interval

  4. Safety and tolerability of SPYK04 (Electrocardiograms in triplicate) [Dose escalation]

    Time frame: From first dose until the end of Cycle 1 (approximately 35 days)

    Heart Rate

  5. Pharmacokinetics of SPYK04 [Dose escalation]

    Time frame: From Cycle 0 Day 1 until 28 days after the last dose of study treatment, assessed up to 42 months (study completion)

    Plasma concentrations of SPYK04

  6. Pharmacokinetics of SPYK04 [Dose escalation]

    Time frame: From Cycle 0 Day 1 until 28 days after the last dose of study treatment, assessed up to 42 months (study completion)

    Maximum plasma concentration (Cmax) of SPYK04

  7. Pharmacokinetics of SPYK04 [Dose escalation]

    Time frame: From Cycle 0 Day 1 until 28 days after the last dose of study treatment, assessed up to 42 months (study completion)

    Time to reach maximum plasma drug concentration (Tmax) of SPYK04

  8. Pharmacokinetics of SPYK04 [Dose escalation]

    Time frame: From Cycle 0 Day 1 until 28 days after the last dose of study treatment, assessed up to 42 months (study completion)

    Area under the concentration versus time curve (AUC) of SPYK04

  9. Preliminary anti-tumor activity of SPYK04 [Cohort expansion]

    Time frame: From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first, assessed up to 42 months (study completion)

    Objective Response Rate (ORR) is defined as proportion of patients who had a confirmed complete response (CR) or partial response (PR), as determined by the investigator with use of Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

Secondary outcomes

  1. Preliminary anti-tumor activity of SPYK04 [Dose escalation]

    Time frame: From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first, assessed up to 42 months (study completion)

    Objective Response

  2. Safety and tolerability of SPYK04 (AEs) [Cohort expansion]

    Time frame: From Cycle 1 Day 1 until 28 days after the last dose of study treatment, assessed up to 42 months (study completion)

    Incidence, nature, and severity of AEs assessed by the NCI CTCAE v5.0

  3. Preliminary anti-tumor activity of SPYK04 [Cohort expansion]

    Time frame: From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first, assessed up to 42 months (study completion)

    Disease control rate (DCR) is defined as proportion of patients who had an objective response or stable disease (SD), as determined by the investigator with use of RECIST v1.1

  4. Preliminary anti-tumor activity of SPYK04 [Cohort expansion]

    Time frame: From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first, assessed up to 42 months (study completion)

    Progression-free survival (PFS) is defined as the time from the first study treatment to the first occurrence of progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurs first

  5. Preliminary anti-tumor activity of SPYK04 [Cohort expansion]

    Time frame: From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first, assessed up to 42 months (study completion)

    Duration of response (DoR) is defined for patients with a CR or PR at the time from the first documented CR or PR to documented disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first

  6. Pharmacokinetics of SPYK04 [Cohort expansion]

    Time frame: From Cycle 1 Day 1 until 28 days after the last dose of study treatment, assessed up to 42 months (study completion)

    Plasma concentrations of SPYK04

  7. Pharmacokinetics of SPYK04 [Cohort expansion]

    Time frame: From Cycle 1 Day 1 until 28 days after the last dose of study treatment, assessed up to 42 months (study completion)

    Maximum plasma concentration (Cmax) of SPYK04

  8. Pharmacokinetics of SPYK04 [Cohort expansion]

    Time frame: From Cycle 1 Day 1 until 28 days after the last dose of study treatment, assessed up to 42 months (study completion)

    Time to reach maximum plasma drug concentration (Tmax) of SPYK04

  9. Pharmacokinetics of SPYK04 [Cohort expansion]

    Time frame: From Cycle 1 Day 1 until 28 days after the last dose of study treatment, assessed up to 42 months (study completion)

    Area under the concentration versus time curve (AUC) of SPYK04

  10. Pharmacodynamics of SPYK04 [Cohort expansion]

    Time frame: From screening until the time of partial response or stable disease lasting for more than 4 months, and the time of progressive disease, if possible, an average of 1 year

    Expression level of pMEK and pERK in solid tumor tissues (e.g., baseline archival or biopsy, and on treatment biopsy)

Sponsors and collaborators

Lead sponsor

Chugai Pharmaceutical

Industry

Registry information

Official study title

A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Aug 13, 2020
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.